试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
编号:NCT03773302登记状态:提前终止企业 / 申办者:QED Therapeutics, a BridgeBio company
药物 / 成分:BGJ398、Gemcitabine、Cisplatin
登记的停止原因(原文):The sponsor has decided to close the study due to the discontinuation of infigratinib development in oncology within the sponsor's territory. The discontinuation of the study was not due to safety issues.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
编号:NCT03942211登记状态:提前终止企业 / 申办者:Actelion
药物 / 成分:Selexipag、Placebo
登记的停止原因(原文):The sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
编号:NCT04112199登记状态:提前终止企业 / 申办者:BioVie Inc.
药物 / 成分:BIV201 continuous infusion
登记的停止原因(原文):For reasons unrelated to safety or efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
编号:NCT04203498登记状态:提前终止企业 / 申办者:Jazz Pharmaceuticals
药物 / 成分:Nabiximols、Placebo
登记的停止原因(原文):This study was terminated based on a business decision by the Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
编号:NCT04374253登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Gantenerumab、Gantenerumab
登记的停止原因(原文):Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
编号:NCT05179057登记状态:提前终止企业 / 申办者:AlloVir
药物 / 成分:Posoleucel、Placebo
登记的停止原因(原文):Study discontinued as DSMB determined it was futile. No safety concerns were noted.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-08
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
编号:NCT05716295登记状态:提前终止企业 / 申办者:Medikine, Inc.
药物 / 成分:MDK-703、Checkpoint Inhibitor, Immune
登记的停止原因(原文):Corporate decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-07
Amlexanox for Type 2 Diabetes and Obesity
编号:NCT01842282登记状态:提前终止企业 / 申办者:University of Michigan
药物 / 成分:Amlexanox
登记的停止原因(原文):Due to limited funding, trial was suspended, intending to restart with additional funds; then preliminary results were obtained, and research moved on to placebo controlled trial. Results for both have been published.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-07
Albuterol to Improve Respiratory Strength in SCI
编号:NCT02508311登记状态:提前终止企业 / 申办者:VA Office of Research and Development
药物 / 成分:Oral Albuterol Extended Release、Placebo
登记的停止原因(原文):Our ability to test subjects with tetraplegia in this interventional study was interrupted by the COVID-19 pandemic. Our research pharmacist also informed us that oral albuterol is no longer being manufactured.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-07
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
编号:NCT02635061登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:ACY-241、Nivolumab
登记的停止原因(原文):Lack of efficacy
查看官方原始记录 ↗